Acoustic Cardiographic Assessment of Heart Function in Comparison to Doppler-echocardiography

Not Applicable

Completed

• Conditions: Heart Failure, Congestive; Antineoplastic Agents

• Registration Number: NCT00541801
• Lead Sponsor: Luzerner Kantonsspital

Brief Summary

In this study, the investigators sought to determine whether an acoustic cardiographic assessment of heart function is equivalent to Doppler-echocardiography in patients who are treated with cardio-toxic cytostatic agents.

Detailed Description

Patients receiving cardio-toxic cytostatic agents are examined by Doppler-echocardiography and acoustic cardiography before, during, and after the cytostatic treatment. Doppler-echocardiography measures ejection fraction, TDI, speckle tracking, and further parameters. Acoustic cardiography (Audicor, Inovise Medical Inc., Portland, USA) simultaneously integrates heart sounds and single-channel electrocardiography input to generate multiple parameters that correlate to established hemodynamic measures. Heart function as assessed by Doppler-echocardiography is then compared to the heart function as assessed by Audicor ECG.

Study Timeline

• Study Start: 2007-03
• Study First Submitted: 2007-10-08
• Study First Submitted QC: 2007-10-09
• Study First Posted: 2007-10-10
• Status Verified: 2011-06
• Primary Completion: 2011-06
• Study Completion: 2011-06
• Last Update Submitted: 2011-06-22
• Last Update Posted: 2011-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Patients with malignant disease with scheduled anthracycline and trastuzumab therapy

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Changes of echocardiographic parameters and changes of electromechanical activation time (EMAT)and development of third heart sound as indicators of congestive heart failure	Repeated measurements over a year

Secondary Outcome Measures

Name	Time	Method
Development of clinically overt congestive heart failure	One year

Trial Locations

Locations (1)

Kantonsspital Luzern, Department of Cardiology; 🇨🇭 Luzern, Switzerland